Publications

Showing 25 results out of 113 in total.

Jones L. The Great Debate: Silicone Hydrogels or Hydrogels? Synoptik, Oslo, Norway, April 18, 2024

Jones L. TFOS Dry Eye Workshop III - Management and therapy of dry eye disease Tear Film & Ocular Surface Society Conference, Venice, Italy, Nov 1, 2024

Jones L. Compliance and its impact on solutions ECLSO, Istanbul, Turkey, April 26, 2024

Jones L. Impact of contact lenses on the ocular surface ECLSO, Istanbul, Turkey, April 27, 2024

Jones L, Morgan P. Corneal Infiltrative Events (CIEs) and Contact Lenses: Avoidable or Not? NCC, Veldhoven, Netherlands, Mar 10, 2024

Jones L, Morgan P, Closson C. Contact Lens Comfort Drivers: Fact Vs. Myth - Option 1 Global Vision Summit 2024, Virtual Session, Mar 20, 2024

Jones L, Morgan P, Closson C. Correcting Low Astigmatism with Toric Soft Contact Lenses – Is It Worth It? - Option 1 Global Vision Summit 2024, Virtual Session, Mar 20, 2024

Jones L, Morgan P, Closson C. Multifocal Contact Lens Fitting: Maximizing Success - Option 1 Global Vision Summit 2024, Virtual Session, Mar 20, 2024

Jones L, Morgan P, Closson C. Contact Lens Comfort Drivers: Fact Vs. Myth - Option 2 Global Vision Summit 2024, Virtual Session, Mar 20, 2024

Jones L, Morgan P, Closson C. Correcting Low Astigmatism with Toric Soft Contact Lenses – Is It Worth It? - Option 2 Global Vision Summit 2024, Virtual Session, Mar 20, 2024

Jones L, Morgan P, Closson C. Multifocal Contact Lens Fitting: Maximizing Success - Option 2 Global Vision Summit 2024, Virtual Session, Mar 20, 2024

Jones L, Schallhorn J, Ng AY, Alster Y, Bosworth C. Sign and Symptom Improvements Rates Among MGD Patients Following Treatment with AZR-MD-001 for 6 Months Tear Film & Ocular Surface Society Conference, Venice, Italy, Nov 2, 2024

Jones L, Schallhorn J, Stapleton F, Alster Y, Bosworth C. AZR-MD-001 Opens Meibomian Glands, Improves Meibum and Tear Quality Resulting in Increased Wear Time and Desired Lens Use in Patients With CLD The Association for Research in Vision and Ophthalmology, Seattle, WA, May 6, 2024 [ Show Abstract ][ PDF ]

Purpose: Contact lens discomfort (CLD) is a common problem for practitioners and wearers. Individuals with CLD experience episodic or persistent ocular discomfort symptoms related to lens wear, including visual disturbances, decreased wear time, or discontinuation overall. AZR MD 001 (AZR) is an ophthalmic keratolytic, keratostatic, and lipogenic ointment containing selenium sulfide, developed to improve signs and symptoms of MGD. This study evaluated if biweekly AZR can open meibomian glands and improve comfortable wear time, allowing patients with CLD who continue to challenge their ocular surface, tear film, and meibomian glands with contact lens use, to wear their contact lenses as desired.

Methods: Adults with CLD and evidence of meibomian gland obstruction (n=67) were randomized (1:1) to AZR 0.5% (n=34) or vehicle (n=33) applied twice weekly at bedtime for 3 months in a Phase 2, multi-center, single-masked parallel-group study (NCT05548491). Key efficacy endpoints evaluated were the change from baseline (CFB) at month 3 compared to vehicle in meibomian gland secretion score (MGS), Tear film stability (TBUT) post lens removal, and total and comfortable wear time.

Results: At month 3, AZR 0.5% significantly improved signs (MGS; TBUT) and lens wear time vs vehicle. Mean [SE] CFB in MGS was 13.8 [0.67] vs vehicle 3.8 [0.68], p<0.0001; TBUT was +3.31 s [0.70] vs vehicle 0.65 s [0.72], p<0.0001; and total comfortable wear time was +192 min [38.07] vs vehicle +2.9 min [38.01], p<0.0001. Significantly more patients, who were unable to comfortably wear contact lenses as desired at baseline, were able to wear them as long as desired by month 3 (42.5% vs vehicle 6.2%, p=0.0015). Improvements over vehicle were first seen on Day 14 in MGS (Mean [SE] CFB 3.2 [0.97] vs vehicle 0.8 [0.91], p<0.0007) and at Month 1 for comfortable wear time +41.6 minutes [24.04] vs vehicle -14.2 minutes [24.04], p=0.0111. All treatment-emergent adverse events (TEAEs) (47/47, 100%) in the 0.5% group were mild to moderate. There were no discontinuations due to a TEAE.

Conclusion: AZR MD 001 significantly improved the meibum and tear film quality, resulting in improved wear time in patients with CLD compared to vehicle starting as early as 8 doses of treatment. AZR demonstrated efficacy, safety, and tolerability, with no major adverse events observed.

Jones L, van Tilborg M. Contact lens wear and artificial tears, a good or a bad marriage? Synoptik, Oslo, Norway, April 18, 2024

Jones L, Willcox M. Contact lens care is the key to improve contact lens discomfort - From recent research The 66th Annual Meeting of the Japan Contact Lens Society, Tokyo, Japan, Jul 15, 2024

Laughton,D., Hill,J. S., McParland,M., Tasso,V., Woods,J., Zhu,X., Young,G., Craven,R., Hunt,C., Neitz,J., Neitz,M., Chalberg,T., Jones,D., Wolffsohn,J. Control of myopia using diffusion optics spectacle lenses: 4-year results of a multicentre randomised controlled, efficacy and safety study (CYPRESS) BMJ Open Ophthalmology 2024;9.e001790 [ Show Abstract ]

Aims To evaluate the myopia control efficacy of Diffusion Optics Technology (DOT) spectacle lenses in children over a 4-year treatment period.

Methods CYPRESS Part 1 (NCT03623074) was a 3-year multicentre, randomised, controlled, double-masked trial comparing two investigational spectacle lens DOT designs (Test 1, Test 2) and standard single vision Control lenses in 256 North American children aged 6–10 years. Children completing Part 1 (n=200) were invited to enrol in CYPRESS Part 2 (NCT04947735) for an additional 1-year period. In Part 2, Test 1 (n=35) and Control groups (n=42) continued with their original lens assignment and the Test 2 group (n=21) were crossed over to Test 1 (DOT 0.2) lenses. The co-primary endpoints were change from baseline in axial length (AL) and cycloplegic spherical equivalent refraction (cSER).

Results Test 1 spectacle lenses demonstrated superiority to the Control in both co-primary endpoints: with a difference between means (Test 1−Control) of −0.13 mm for AL (p=0.018) and 0.33 D for cSER (p=0.008) in Part 1 and −0.05 mm for AL (p=0.038) and 0.13 D for cSER (p=0.043) in Part 2. Comparing treatment effects in Part 1 and 2 suggests that COVID-19 public health restrictions negatively impacted treatment efficacy in study years 2 and 3.

Conclusion DOT 0.2 spectacle lenses are safe and effective at reducing myopia progression, with additional benefit evident in year 4 of wear. These results support the hypothesis that a mild reduction in retinal contrast can slow myopia progression in young children. The unprecedented disruption in participant schooling and lifestyle during the COVID-19 pandemic may have depressed treatment efficacy in Part 1.

Luensmann D. Can we mask corneal astigmatism with soft lenses? https://contactlensupdate.com/2024/06/19/can-we-mask-corneal-astigmatism-with-soft-lenses/ 2024, 78:

Luensmann D. Fast Forward to the Future: Regaining Accommodation: Which Way to Go? Contact Lens Spectrum 2024;39, July:

Luensmann D. Practitioner Reference: Optimize Multifocal Soft Lens Fitting
https://contactlensupdate.com/2024/10/03/practitioner-reference-optimize-multifocal-soft-lens-fitting/ 2024, 80:

Mahil A, Jong M. Truth or myth: Only high levels of myopia increase the risk of ocular disease and permanent vision loss? Optician: https://www.opticianonline.net/content/features/truth-or-myth-only-high-levels-of-myopia-increase-the-risk-of-ocular-disease-and-permanent-vision-loss-answer-myth/ 2024, February 1:

McKinney M, Irving E, Jones D, Christian L. Parental Compliance in Response to Vision Screenings in Waterloo, Canada American Academy of Optometry Meeting, Indianapolis, Nov 7, 2024

Mishra,S. K., Baidya,S., Bhattarai,A., Shrestha,S., Homagan,S., Rayamajhee,B., Hui,A., Willcox,M. Bacteriology of Endotracheal Tube Biofilms and Antibiotic Resistance: A Systematic Review Journal of Hospital Infection 2024;Online ahead of print [ Show Abstract ]

Background
Bacteria commonly adhere to surfaces and produce polymeric material to encase the attached cells to form communities called biofilms. Within these biofilms, bacteria can appear many times more resistant to antibiotics or disinfectants. This systematic review explores the prevalence and microbial profile associated with biofilm production of bacteria isolated from endotracheal tubes and its associations with antimicrobial resistance.

Methods
A comprehensive search was performed on databases PubMed, Embase, and Google Scholar for relevant articles published between January 1, 2000 and December 31, 2022. The relevant articles were exported to Mendeley Desktop 1.19.8 and screened by title and abstract, followed by full text screening based on the eligibility criteria of the study. Quality assessment of the studies was performed using the Newcastle-Ottawa Scale (NOS) customized for cross-sectional studies. Furthermore, the prevalence of antimicrobial resistance in biofilm-producers isolated from endotracheal tube specimens was investigated.

Results
Twenty studies encompassing 981 endotracheal tubes met the eligibility criteria. Pseudomonas spp. and Acinetobacter spp. were predominant isolates among the biofilm producers. These biofilms provided strong resistance against commonly used antibiotics. The highest resistance rate observed in Pseudomonas spp. was against fluoroquinolones whereas the least resistance was seen against piperacillin-tazobactam. A similar trend of susceptibility was observed in Acinetobacter spp. with a very high resistance rate against fluoroquinolones, third-generation cephalosporins and carbapenems.

Conclusion
Endotracheal tubes were associated with colonisation by biofilm forming bacteria with varying levels of antimicrobial resistance. Biofilms may promote the occurrence of recalcitrant infections in endotracheal tubes which need to be managed with appropriate protocols and antimicrobial stewardship. Research focus should shift towards meticulous exploration of biofilm-associated infections to improve detection and management.

Moezzi A, Moghadas M, Laachiri K, Lamrani M, Woods J, Jones L, Ngo W. Dry Eye Diagnostic Efficacy of Novel Ocular Thermography Metrics American Academy of Optometry Meeting, Indianapolis, Nov 8, 2024

Moezzi A, Ruston D. Truth or myth: Daily disposable hydrogel wearers should be refitted into DD silicone hydrogel lenses? Optician: https://www.opticianonline.net/content/features/truth-or-myth-daily-disposable-hydrogel-wearers-should-be-refitted-into-dd-silicone-hydrogel-lenses/ 2024, April 5:

Mohseni,M., Shokrollahi,P., Barzin, J. Gelatin/O-carboxymethyl chitosan injectable self-healing hydrogels for ibuprofen and naproxen dual release International Journal of Biological Macromolecules 2024;263, Part 1(April):Art No 130266